Is seroquel developing an illicit reputation for misuse/abuse?

Psychiatry

Volumn 7, Issue 1, 2010, Pages 13-16

  Sansone, Randy A ^a,b   Sansone, Lori A ^c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b KETTERING MEDICAL CENTER   (United States)

^c WRIGHT PATTERSON AIR FORCE BASE   (United States)

Author keywords

Abuse; Misuse; Quetiapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE;

ARTICLE; DROWSINESS; DRUG ABUSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MISUSE; DRUG RECEPTOR BINDING; HUMAN; MENTAL PATIENT; PRISONER; SEDATION; SIDE EFFECT; SOMNOLENCE; SUBSTANCE ABUSE; TRANQUILIZING ACTIVITY;

EID: 77649095652     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. FDA wants more information on Seroquel XR in GAD from AstraZeneca. Available at: http://www.pharmatimes.com/WorldNews/article.aspx?id= 15398&src=WorldNewsRSS. Accessed on 3/31/09.
2. Toscano A. Letter. Available at: http://www.fda.gov/cder/warn/2008/ Seroquel-Ltr.pdf. Accessed on 3/31/09.
3. Gold Standard, Inc. Seroquel. Clinical Pharmacology [database online]. Available at: http://www.clinicalpharmacology.com. Accessed on 3/30/09.
4. Paparrigopoulos T, Karaiskos D, Liappas J. Quetiapine: another drug with potential for misuse? A case report. J Clin Psychiatry. 2008;69:162-163.
5. Murphy D, Bailey K, Stone M, Wirshing WC. Addictive potential of quetiapine. Am J Psychiatry. 2008;165:918.
6. Reeves RR, Brister JC. Additional evidence of the abuse potential of quetiapine. S Med J. 2007;100:834-836.
7. Pinta ER, Taylor RE. Quetiapine addiction? Am J Psychiatry. 2007;164:174-175.
8. Morin AK. Possible intranasal quetiapine misuse. Am J Health Syst Pharm. 2007;64:723-725.
9. Waters BM, Joshi KG. Intravenous quetiapine-cocaine use ("Q-ball"). Am J Psychiatry. 2007;164:173-174.
10. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse. Am J Psychiatry. 2005;162:1755-1756.
11. Pierre JM, Shnayder I, Wirshing DA, Wirshing WC. Intranasal quetiapine abuse. Am J Psychiatry. 2004;161:1718.
12. Keltner NL, Vance DE. Incarcerated care and quetiapine abuse. Perspect Psychiatr Care. 2008;44:202-206.
13. Hanley MJ, Kenna GA. Quetiapine: treatment for substance abuse and drug of abuse. Am J Health Syst Pharm. 2008;65:611-618.
14. Gugger JJ, Cassagnol M. Low-dose quetiapine is not a benign sedative-hypnotic agent. Am J Addict. 2008;17:454-455.
15. Tarasoff G, Osti K. Black-market value of antipsychotics, antidepressants, and hypnotics in Las Vegas, Nevada. Am J Psychiatry. 2007;164:350.
16. Tcheremissine OV. Is quetiapine a drug of abuse? Reexamining the issue of addiction. Expert Opin Drug Saf. 2008;7:739-748.
17. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical review. CMAJ. 2005;172:1703-1711.
18. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389-409.
19. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion. 2004;6:3-7S.
20. Tandon R, Targum SD, Nasrallah HA, Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Pract. 2006;12:348-363.
21. Twaites BR, Wilton LV, Shakir SA. The safety of quetiapine: results of a postmarketing surveillance study on 1728 patients in England. J Psychopharmacol. 2007;21:392-399.
22. Goldstein J, Zhong K. Tolerance to somnolence with quetiapine ("Seroquel"): preclinical mechanisms and clinical evidence. Presented at the XXIV Collegium Internationale Neuro-Psychopharmacologicum; June 2004; Paris, France.
23. Kennedy A, Wood AE, Saxon AJ, et al. Quetiapine for the treatment of cocaine dependence: an open-label trial. J Clin Psychopharmacol. 2008;28:221-224.
24. Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24:532-535.
25. Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol. 2008;23:417-424.
26. Sattar SP, Schultz SK, Arndt S, et al. Long-term adjunctive quetiapine may reduce substance use-a preliminary retrospective study. S D Med. 2007;60:439-441.
27. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci. 2004;29:452-457.
28. Potvin S, Stip E, Roy J-Y. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry. 2004;49:711.
29. Pinkofsky HB, Hahn AM, Campbell FA, et al. Reduction of opioid-withdrawal symptoms with quetiapine. J Clin Psychiatry. 2005;66:1285-1288.